Contrarily, clinical studies showed that IL-21 can promote the proliferation of Hodgkin lymphoma (99), EBV transformed lymphomas (100) and ALK-positive anaplastic large cell lymphoma (101) suggesting that blocking the effect of IL-21 may be a potential therapeutic approaches in these lymphoma subtypes. This evidence concerns the gene IL21 and anaplastic large cell lymphoma.